Argatroban in Thrombotic Stroke
- 1 January 2002
- journal article
- review article
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 32 (Suppl. 3) , 39-45
- https://doi.org/10.1159/000069108
Abstract
Evidence for the potential use of direct thrombin inhibition in the treatment of acute stroke is reviewed. Reduction of secondary microthrombi and improved regional collateral cerebral blood flow is the proposed mechanism of action of thrombin inhibition for the treatment of cerebral ischemia. A clinical study in Japan found that argatroban administered within 48 h of stroke symptom onset is safe and effective in reducing neurological impairment due to ischemic stroke. The implications of further clinical studies are discussed.Keywords
This publication has 3 references indexed in Scilit:
- CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic strokeThe Lancet, 1997
- The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic strokePublished by Elsevier ,1997
- Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitorThrombosis Research, 1985